Study shows promising multiple sclerosis treatment targets immune cells to increase neuroprotection
Laquinimod is an orally available synthetic compound that has been successfully evaluated in phase II/III clinical studies for the treatment of relapsing-remitting multiple sclerosis (RRMS). The mechanism of action of laquinimod ...
Dec 6, 2011
0
0